Targeting the future in head and neck cancer.
Publication
, Journal Article
Brizel, DM
Published in: Lancet Oncol
March 2009
Duke Scholars
Published In
Lancet Oncol
DOI
EISSN
1474-5488
Publication Date
March 2009
Volume
10
Issue
3
Start / End Page
204 / 205
Location
England
Related Subject Headings
- Vascular Endothelial Growth Factor A
- Quinazolines
- Oncology & Carcinogenesis
- Humans
- Head and Neck Neoplasms
- Erlotinib Hydrochloride
- ErbB Receptors
- Carcinoma, Squamous Cell
- Bevacizumab
- Antineoplastic Combined Chemotherapy Protocols
Citation
APA
Chicago
ICMJE
MLA
NLM
Brizel, D. M. (2009). Targeting the future in head and neck cancer. Lancet Oncol, 10(3), 204–205. https://doi.org/10.1016/S1470-2045(09)70051-8
Brizel, David M. “Targeting the future in head and neck cancer.” Lancet Oncol 10, no. 3 (March 2009): 204–5. https://doi.org/10.1016/S1470-2045(09)70051-8.
Brizel DM. Targeting the future in head and neck cancer. Lancet Oncol. 2009 Mar;10(3):204–5.
Brizel, David M. “Targeting the future in head and neck cancer.” Lancet Oncol, vol. 10, no. 3, Mar. 2009, pp. 204–05. Pubmed, doi:10.1016/S1470-2045(09)70051-8.
Brizel DM. Targeting the future in head and neck cancer. Lancet Oncol. 2009 Mar;10(3):204–205.
Published In
Lancet Oncol
DOI
EISSN
1474-5488
Publication Date
March 2009
Volume
10
Issue
3
Start / End Page
204 / 205
Location
England
Related Subject Headings
- Vascular Endothelial Growth Factor A
- Quinazolines
- Oncology & Carcinogenesis
- Humans
- Head and Neck Neoplasms
- Erlotinib Hydrochloride
- ErbB Receptors
- Carcinoma, Squamous Cell
- Bevacizumab
- Antineoplastic Combined Chemotherapy Protocols